Pirenzepine is under clinical development by Winsantor and currently in Phase II for Chemotherapy Induced Peripheral Neuropathy. According to GlobalData, Phase II drugs for Chemotherapy Induced Peripheral Neuropathy does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Pirenzepine LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pirenzepine (WST-057) is under development for the treatment of diabetic peripheral neuropathy, chemotherapy induced peripheral neuropathy and HIV related associated distal sensory polyneuropathy (DSP). The drug candidate is applied topically. It acts by targeting muscarinic acetylcholine type 1 receptors (M1R).
It was also under development for the treatment of Pain.
Winsantor., is a biotechnology company that focused on the discovery and development of treatments for peripheral neuropathies. The company is headquartered in United States.
For a complete picture of Pirenzepine’s drug-specific PTSR and LoA scores, buy the report here.